Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997

A report from the Children's Oncology Group

R. Beverly Raney, James R. Anderson, Kenneth L.B. Brown, Winston W. Huh, Harold Maurice Maurer, William H. Meyer, David M. Parham, David A. Rodeberg, Suzanne L. Wolden, Sarah S. Donaldson

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: To assess local control, event-free survival (EFS), and overall survival (OS) rates in 71 patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma (ALV RMS) and their relation to radiation therapy (RT) on IRSG Protocols III and IV, 1984-1997. Methods: Chart review and standard statistical procedures. Patients and Tumors: Patients were 1-18 years at diagnosis (median, 6 years). Primary tumor sites were extremity/trunk (N = 54), head/neck (N = 9), genitourinary tract (N = 7), and perineum (N = 1). Thirty patients received VA ± C with RT; 41 received VA ± C alone. RT was assigned, not randomized. Results: Fifty-four patients had Stage 1 (favorable site, any size) or Stage 2 (unfavorable site, ≤5 cm) tumors. Eight-year EFS was 90%, with 100% local control for 17 patients given RT. Eight-year EFS was 88%, with 92% local control for 37 patients without RT; P = 0.52 for EFS comparisons, 0.3 for local control comparisons. In 17 Stage 3 patients (unfavorable site, tumors >5 cm, N0), 8-year EFS was 84% with 100% local control in 13 patients given RT; 8-year EFS was only 25% and local control 50% in 4 patients without RT. Local recurrence was the most common site of first failure in non-irradiated patients. Conclusion: Patients with Stage 1-2 ALV RMS had slightly but statistically insignificantly improved local control, EFS, and OS rates when local RT was given. The need for local RT in Stage 1-2 patients deserves evaluation in a randomized study. Local control, EFS, and OS rates were significantly improved in Stage 3 patients receiving local RT. Pediatr Blood Cancer.

Original languageEnglish (US)
Pages (from-to)612-616
Number of pages5
JournalPediatric Blood and Cancer
Volume55
Issue number4
DOIs
StatePublished - Oct 1 2010

Fingerprint

Alveolar Rhabdomyosarcoma
Rhabdomyosarcoma
Radiotherapy
Disease-Free Survival
Therapeutics
Survival Rate
Neoplasms
Perineum

Keywords

  • Pediatric oncology
  • Rhabdomyosarcoma
  • Soft tissue sarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997 : A report from the Children's Oncology Group. / Raney, R. Beverly; Anderson, James R.; Brown, Kenneth L.B.; Huh, Winston W.; Maurer, Harold Maurice; Meyer, William H.; Parham, David M.; Rodeberg, David A.; Wolden, Suzanne L.; Donaldson, Sarah S.

In: Pediatric Blood and Cancer, Vol. 55, No. 4, 01.10.2010, p. 612-616.

Research output: Contribution to journalArticle

Raney, R. Beverly ; Anderson, James R. ; Brown, Kenneth L.B. ; Huh, Winston W. ; Maurer, Harold Maurice ; Meyer, William H. ; Parham, David M. ; Rodeberg, David A. ; Wolden, Suzanne L. ; Donaldson, Sarah S. / Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997 : A report from the Children's Oncology Group. In: Pediatric Blood and Cancer. 2010 ; Vol. 55, No. 4. pp. 612-616.
@article{a4d1631f543e4714a999838fa79945c0,
title = "Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997: A report from the Children's Oncology Group",
abstract = "Purpose: To assess local control, event-free survival (EFS), and overall survival (OS) rates in 71 patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma (ALV RMS) and their relation to radiation therapy (RT) on IRSG Protocols III and IV, 1984-1997. Methods: Chart review and standard statistical procedures. Patients and Tumors: Patients were 1-18 years at diagnosis (median, 6 years). Primary tumor sites were extremity/trunk (N = 54), head/neck (N = 9), genitourinary tract (N = 7), and perineum (N = 1). Thirty patients received VA ± C with RT; 41 received VA ± C alone. RT was assigned, not randomized. Results: Fifty-four patients had Stage 1 (favorable site, any size) or Stage 2 (unfavorable site, ≤5 cm) tumors. Eight-year EFS was 90{\%}, with 100{\%} local control for 17 patients given RT. Eight-year EFS was 88{\%}, with 92{\%} local control for 37 patients without RT; P = 0.52 for EFS comparisons, 0.3 for local control comparisons. In 17 Stage 3 patients (unfavorable site, tumors >5 cm, N0), 8-year EFS was 84{\%} with 100{\%} local control in 13 patients given RT; 8-year EFS was only 25{\%} and local control 50{\%} in 4 patients without RT. Local recurrence was the most common site of first failure in non-irradiated patients. Conclusion: Patients with Stage 1-2 ALV RMS had slightly but statistically insignificantly improved local control, EFS, and OS rates when local RT was given. The need for local RT in Stage 1-2 patients deserves evaluation in a randomized study. Local control, EFS, and OS rates were significantly improved in Stage 3 patients receiving local RT. Pediatr Blood Cancer.",
keywords = "Pediatric oncology, Rhabdomyosarcoma, Soft tissue sarcoma",
author = "Raney, {R. Beverly} and Anderson, {James R.} and Brown, {Kenneth L.B.} and Huh, {Winston W.} and Maurer, {Harold Maurice} and Meyer, {William H.} and Parham, {David M.} and Rodeberg, {David A.} and Wolden, {Suzanne L.} and Donaldson, {Sarah S.}",
year = "2010",
month = "10",
day = "1",
doi = "10.1002/pbc.22520",
language = "English (US)",
volume = "55",
pages = "612--616",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997

T2 - A report from the Children's Oncology Group

AU - Raney, R. Beverly

AU - Anderson, James R.

AU - Brown, Kenneth L.B.

AU - Huh, Winston W.

AU - Maurer, Harold Maurice

AU - Meyer, William H.

AU - Parham, David M.

AU - Rodeberg, David A.

AU - Wolden, Suzanne L.

AU - Donaldson, Sarah S.

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Purpose: To assess local control, event-free survival (EFS), and overall survival (OS) rates in 71 patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma (ALV RMS) and their relation to radiation therapy (RT) on IRSG Protocols III and IV, 1984-1997. Methods: Chart review and standard statistical procedures. Patients and Tumors: Patients were 1-18 years at diagnosis (median, 6 years). Primary tumor sites were extremity/trunk (N = 54), head/neck (N = 9), genitourinary tract (N = 7), and perineum (N = 1). Thirty patients received VA ± C with RT; 41 received VA ± C alone. RT was assigned, not randomized. Results: Fifty-four patients had Stage 1 (favorable site, any size) or Stage 2 (unfavorable site, ≤5 cm) tumors. Eight-year EFS was 90%, with 100% local control for 17 patients given RT. Eight-year EFS was 88%, with 92% local control for 37 patients without RT; P = 0.52 for EFS comparisons, 0.3 for local control comparisons. In 17 Stage 3 patients (unfavorable site, tumors >5 cm, N0), 8-year EFS was 84% with 100% local control in 13 patients given RT; 8-year EFS was only 25% and local control 50% in 4 patients without RT. Local recurrence was the most common site of first failure in non-irradiated patients. Conclusion: Patients with Stage 1-2 ALV RMS had slightly but statistically insignificantly improved local control, EFS, and OS rates when local RT was given. The need for local RT in Stage 1-2 patients deserves evaluation in a randomized study. Local control, EFS, and OS rates were significantly improved in Stage 3 patients receiving local RT. Pediatr Blood Cancer.

AB - Purpose: To assess local control, event-free survival (EFS), and overall survival (OS) rates in 71 patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma (ALV RMS) and their relation to radiation therapy (RT) on IRSG Protocols III and IV, 1984-1997. Methods: Chart review and standard statistical procedures. Patients and Tumors: Patients were 1-18 years at diagnosis (median, 6 years). Primary tumor sites were extremity/trunk (N = 54), head/neck (N = 9), genitourinary tract (N = 7), and perineum (N = 1). Thirty patients received VA ± C with RT; 41 received VA ± C alone. RT was assigned, not randomized. Results: Fifty-four patients had Stage 1 (favorable site, any size) or Stage 2 (unfavorable site, ≤5 cm) tumors. Eight-year EFS was 90%, with 100% local control for 17 patients given RT. Eight-year EFS was 88%, with 92% local control for 37 patients without RT; P = 0.52 for EFS comparisons, 0.3 for local control comparisons. In 17 Stage 3 patients (unfavorable site, tumors >5 cm, N0), 8-year EFS was 84% with 100% local control in 13 patients given RT; 8-year EFS was only 25% and local control 50% in 4 patients without RT. Local recurrence was the most common site of first failure in non-irradiated patients. Conclusion: Patients with Stage 1-2 ALV RMS had slightly but statistically insignificantly improved local control, EFS, and OS rates when local RT was given. The need for local RT in Stage 1-2 patients deserves evaluation in a randomized study. Local control, EFS, and OS rates were significantly improved in Stage 3 patients receiving local RT. Pediatr Blood Cancer.

KW - Pediatric oncology

KW - Rhabdomyosarcoma

KW - Soft tissue sarcoma

UR - http://www.scopus.com/inward/record.url?scp=77957106422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957106422&partnerID=8YFLogxK

U2 - 10.1002/pbc.22520

DO - 10.1002/pbc.22520

M3 - Article

VL - 55

SP - 612

EP - 616

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -